# Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

> **NCT04472767** · PHASE2 · RECRUITING · sponsor: **University of California, Irvine** · enrollment: 35 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- HCC

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Cabozantinib
- **PROCEDURE:** Transarterial Chemoembolization

## Key facts

- **NCT ID:** NCT04472767
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-07
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04472767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04472767, "Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04472767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*